DP
ONC

Diadema Partners’s BeOne Medicines Ltd ONC Stock Holding History

Diadema Partners’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,500
Closed -$173K – 218
2025
Q4 		$173K Buy
+7,500
New +$2.45M 0.03% 131
2025
Q1 		– Sell
-30,000
Closed -$422K – 161
2024
Q4 		$422K Buy
+30,000
New +$6.13M 0.18% 74

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Diadema Partners's ONC Position: Q1 2026 in Review

Diadema Partners sold out of BeOne Medicines Ltd (ONC) in Q1 2026, closing a stake of 7,500 shares — an estimated $173K sold.

Diadema Partners first reported a position in ONC in Q4 2024 and held it in 2 quarters. The position peaked at $422K in Q4 2024. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Diadema Partners reported no remaining BeOne Medicines Ltd position as of Q1 2026 after selling out during the quarter.
  • Diadema Partners sold 7,500 BeOne Medicines Ltd shares in Q1 2026, an estimated $173K.
  • Diadema Partners first reported a position in BeOne Medicines Ltd in Q4 2024 and held it in 2 quarters.
  • Diadema Partners's BeOne Medicines Ltd position peaked at $422K in Q4 2024.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.